Bank of New York Mellon Corp Acquires 15,543 Shares of Advaxis Inc. (ADXS)
Bank of New York Mellon Corp raised its stake in Advaxis Inc. (NASDAQ:ADXS) by 10.4% during the second quarter, Holdings Channel reports. The fund owned 164,368 shares of the biotechnology company’s stock after buying an additional 15,543 shares during the period. Bank of New York Mellon Corp owned about 0.48% of Advaxis worth $1,330,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Advaxis by 1.2% in the first quarter. Geode Capital Management LLC now owns 183,611 shares of the biotechnology company’s stock valued at $1,658,000 after buying an additional 2,159 shares during the last quarter. Squarepoint Ops LLC increased its position in Advaxis by 210.8% in the first quarter. Squarepoint Ops LLC now owns 63,100 shares of the biotechnology company’s stock valued at $570,000 after buying an additional 42,800 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in Advaxis during the second quarter valued at $629,000. Institutional investors and hedge funds own 55.57% of the company’s stock.
Advaxis Inc. (NASDAQ:ADXS) traded down 2.43% during trading on Wednesday, reaching $10.02. 453,007 shares of the company traded hands. The firm has a 50-day moving average price of $11.17 and a 200-day moving average price of $9.74. Advaxis Inc. has a 52 week low of $5.21 and a 52 week high of $16.30. The company’s market capitalization is $399.24 million.
Several brokerages have recently commented on ADXS. Barclays PLC raised their price objective on shares of Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, August 3rd. Jefferies Group restated a “buy” rating on shares of Advaxis in a research report on Thursday, August 4th. HC Wainwright restated a “buy” rating on shares of Advaxis in a research report on Wednesday, June 29th. Finally, FBR & Co restated an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a research report on Thursday, July 7th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $24.60.
In other Advaxis news, Director Richard J. Berman sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $15.21, for a total transaction of $273,780.00. Following the sale, the director now owns 66,430 shares of the company’s stock, valued at approximately $1,010,400.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David Sidransky sold 22,808 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total transaction of $342,348.08. Following the sale, the director now directly owns 91,759 shares in the company, valued at approximately $1,377,302.59. The disclosure for this sale can be found here. Company insiders own 4.56% of the company’s stock.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis Inc. (NASDAQ:ADXS).
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.